Merck Serono Ventures, Compugen Team Up On Drug Toxicity Biomarker Start-Up
This article was originally published in The Pink Sheet Daily
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.
You may also be interested in...
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.
With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.
Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.